MRI时代预防性全脑照射对局限期小细胞肺癌患者预后的影响
本研究回顾性分析2002年6月至2017年1月收治的620例局限期小细胞肺癌患者,评估MRI监测时代预防性全脑照射(PCI)对预后的影响。结果显示PCI显著降低完全缓解(CR)和部分缓解(PR)患者的累积脑转移率,但仅PR患者的总生存获益,CR患者总生存无显著改善。作者认为需进一步前瞻性随机研究。
要点
- CR患者中,接受PCI者累积脑转移率17.1% vs 未接受者37.9%(P=0.011),但总生存无显著差异(P=0.98)。
- PR患者中,接受PCI者累积脑转移率12.7% vs 未接受者46.2%(P=0.000),中位生存25.7个月 vs 18.6个月。
- 基线KPS≥90是CR和PR患者总生存的有利独立预后因素。
核心结论
- 在局限期小细胞肺癌患者中,PCI显著降低CR和PR患者的累积脑转移率,但对CR患者总生存无显著正面影响。
- 作者认为需进一步前瞻性随机研究。
研究设计与样本
- 回顾性分析2002年6月至2017年1月收治的620例经根治性放化疗后达到CR或PR的局限期小细胞肺癌患者。
- 采用Kaplan-Meier法计算生存数据,Cox比例风险模型进行多因素预后分析。
主要发现
- CR患者228例(36.8%),其中29例未接受PCI,其余199例中172例(86.4%)在PCI前接受脑MRI排除脑转移;中位随访25.6个月,接受与未接受PCI者累积脑转移率分别为17.1%和37.9%(P=0.011),中位生存时间分别为30.2个月和30.5个月,1年、3年、5年生存率分别为93.7%、42.9%、35.8%和83.4%、46.5%、41.9%(P=0.98)。
- CR患者多因素分析显示基线KPS≥90是总生存的有利独立预后因素(HR: 0.33, 95% CI: 0.23-0.46, P=0.000)。
- PR患者392例(63.2%),其中53例未接受PCI,其余339例中310例(91.4%)在PCI前接受脑MRI;中位随访15.5个月,接受与未接受PCI者累积脑转移率分别为12.7%和46.2%(P=0.000),中位生存时间分别为25.7个月和18.6个月,1年、3年、5年生存率分别为87.6%、40.2%、29.2%和75.7%、16.7%、10.3%(P=0.000)。
- PR患者多因素分析显示基线KPS≥90(HR: 0.32, 95% CI: 0.25-0.41, P=0.000)和PCI(HR: 0.57, 95% CI: 0.41-0.79, P=0.001)是总生存的有利预后因素。
关键数值与推荐
- CR患者接受PCI者累积脑转移率17.1% vs 未接受者37.9%(P=0.011)。
- PR患者接受PCI者累积脑转移率12.7% vs 未接受者46.2%(P=0.000)。
- CR患者基线KPS≥90的OS HR为0.33(95% CI: 0.23-0.46, P=0.000)。
- PR患者基线KPS≥90的OS HR为0.32(95% CI: 0.25-0.41, P=0.000),PCI的OS HR为0.57(95% CI: 0.41-0.79, P=0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
- 作者在结论中提出需进一步前瞻性随机研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSES: To evaluate the impact of prophylactic cranial irradiation (PCI) on the prognosis of patients with limited-stage small cell lung cancer (SCLC) in the era of MRI surveillance. METHODS: Limited-stage SCLC patients with complete remission (CR) or partial remission (PR) of tumor after definitive chemo-radiotherapy (CRT) were retrospectively analyzed. Survival data were calculated by Kaplan-Meier methods, Cox proportional hazards model was applied for multivariate prognostic analysis. RESULTS: Between June 2002 and January 2017, 620 patients with limited-stage SCLC were accrued in our study. After CRT, 228 (36.8%) patients achieved CR, of whom, 29 patients did not receive PCI, among the rest 199 patients, 172 (86.4%) received brain MRI to exclude brain metastasis (BM) before PCI. With a median follow-up time of 25.6 months, the cumulative BM rate was 17.1% and 37.9% in patients who received or did not receive PCI (P = 0.011). The median survival time was 30.2 months and 30.5 months, respectively and the 1 -, 3 -, 5-year survival rates were 93.7%, 42.9%, 35.8% and 83.4%, 46.5%, 41.9%, respectively (P = 0.98). Multivariate analysis indicated that baseline KPS ≥ 90 was a favorable independent prognostic factor for OS in CR patients (HR: 0.33, 95% CI: 0.23-0.46, P = 0.000). After CRT, 392 (63.2%) patients achieved PR, 53 cases did not receive PCI and 310 (91.4%) of the remaining 339 patients received brain MRI before PCI. With a median follow-up time of 15.5 months, the cumulative brain metastasis rate was 12.7% and 46.2% respectively (P = 0.000). The median survival time was 25.7 months and 18.6 months, respectively. The 1 -, 3 -, and 5-year survival rates were 87.6%, 40.2%, 29.2% and 75.7%, 16.7%, 10.3% (P = 0.000). Baseline KPS ≥ 90 (HR: 0.32, 95% CI: 0.25-0.41, P = 0.000) and PCI (HR: 0.57, 95% CI: 0.41-0.79, P = 0.001) were favorable prognostic factors for OS in PR patients. CONCLUSIONS: In this study, PCI significantly reduced the incidence of BM in patients with limited-stage SCLC who were evaluated as CR and PR after CRT, but it has no significantly positive impact on overall survival in CR patients. Further prospective randomized studies were warranted.
引用
- Chen M, Sun Z, Pan J, et al. The impact of Prophylactic cranial irradiation on the prognosis of patients with limited-stage small cell lung cancer in the MRI era. Radiat Oncol. 2024. PMID: 39543706. doi:10.1186/s13014-024-02557-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。